Pembrolizumab is NOT recommended for metastatic triple-negative breast cancer with PD-L1 TPS <1%
For patients with metastatic TNBC and PD-L1 TPS <1%, single-agent chemotherapy should be offered as first-line treatment rather than pembrolizumab-based immunotherapy. 1
Evidence-Based Rationale
PD-L1 Expression Threshold is Critical
The KEYNOTE-355 trial, which forms the basis for pembrolizumab approval in metastatic TNBC, demonstrated that benefit was limited to patients with CPS ≥10. In this pivotal trial:
- PD-L1 CPS ≥10: Median PFS improved from 5.6 to 9.7 months (HR 0.65) with pembrolizumab plus chemotherapy 1
- PD-L1 CPS <1: The hazard ratio for PFS was 1.03 (95% CI: 0.65-1.64) and for OS was 1.41 (95% CI: 0.90-2.20), indicating no benefit and potential harm 1
ASCO Guideline Recommendation
The 2021 ASCO guidelines explicitly state: "Patients with metastatic triple-negative breast cancer without expression of programmed cell death ligand-1 (PD-L1–negative) should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment" 1. This recommendation carries a strong strength with moderate evidence quality.
Monotherapy Data Confirms Lack of Benefit
The KEYNOTE-119 trial evaluated pembrolizumab monotherapy versus chemotherapy in previously treated metastatic TNBC. Even in the overall population, pembrolizumab failed to improve OS (9.9 vs 10.8 months, HR 0.97) 2. In PD-L1 negative patients, there would be even less rationale for use.
What You Should Do Instead
First-Line Treatment Options for PD-L1 Negative mTNBC:
Single-agent chemotherapy (preferred approach) 1:
- Taxanes (paclitaxel preferred if not previously used)
- Anthracyclines (if not previously used in neoadjuvant/adjuvant setting)
- Capecitabine
- Eribulin
Combination chemotherapy may be considered only for:
- Symptomatic disease
- Immediately life-threatening disease
- Visceral crisis where time allows only one potential chance for therapy 1
Subsequent Line Options:
- After ≥2 prior therapies: Sacituzumab govitecan (strong recommendation) 1
- Germline BRCA1/2 mutations: PARP inhibitors (olaparib or talazoparib) 1
Critical Pitfalls to Avoid
Do not use pembrolizumab based on:
- TPS alone when CPS is the validated biomarker for KEYNOTE-355
- Hope that "some benefit might exist" - the data show potential harm (HR >1.0 for OS)
- Pressure to use immunotherapy when chemotherapy is more appropriate
Ensure proper PD-L1 testing:
- KEYNOTE-355 used the 22C3 antibody with CPS scoring (not TPS)
- CPS measures PD-L1 on tumor cells, lymphocytes, and macrophages
- TPS <1% likely corresponds to CPS <1%, confirming PD-L1 negativity
Safety Considerations
Even if considering off-guideline use, pembrolizumab adds toxicity without benefit in PD-L1 negative disease:
- Grade 3-4 adverse events: ~70% with pembrolizumab-chemotherapy 1
- Treatment-related deaths occurred in KEYNOTE-355 1
- Immune-related adverse events (thyroid disease 23%, other immune toxicities ~10%) 1
The risk-benefit ratio clearly favors chemotherapy alone in PD-L1 negative mTNBC.